Travere Therapeutics
TVTX
108 hedge funds and large institutions have $792M invested in Travere Therapeutics in 2017 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 43 increasing their positions, 37 reducing their positions, and 15 closing their positions.
374% more call options, than puts
Call options by funds: $8.01M | Put options by funds: $1.69M
16% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 37
5% more capital invested
Capital invested by funds: $753M → $792M (+$38.3M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.18% less ownership
Funds ownership: 107.17% → 106.98% (-0.18%)
5% less funds holding
Funds holding: 114 → 108 (-6)
33% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ORI
Oak Ridge Investments
Chicago,
Illinois
|
+$9.13M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$5.56M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.93M |
| 4 |
Goldman Sachs
New York
|
+$3.32M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$3.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$6.73M |
| 2 |
Millennium Management
New York
|
-$5.96M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$3.65M |
| 4 |
SAM
Senzar Asset Management
New York
|
-$3.34M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.82M |
TVTX Hedge Fund Activity: Q2 2017 in Review
108 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q2 2017, worth a combined $792M — up 5.1% from $753M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of TVTX and 10 opened new positions — a net loss of 5 holders — while 37 trimmed existing stakes and 43 added.
The largest buyer was Oak Ridge Investments, adding an estimated $9.13M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $6.73M sold.
- 108 institutional investors held Travere Therapeutics (TVTX) as of Q2 2017, down from 114 in Q1 2017.
- Funds reported $792M of Travere Therapeutics stock for Q2 2017, up 5.1% quarter-over-quarter.
- 10 funds opened new Travere Therapeutics positions in Q2 2017 and 15 closed out, a net change of -5 holders.
- The largest Travere Therapeutics buyer in Q2 2017 was Oak Ridge Investments, an estimated $9.13M added.
- The largest Travere Therapeutics seller in Q2 2017 was Renaissance Technologies, an estimated $6.73M sold.
Based on aggregated 13F filings for Q2 2017.